Formulary coverage in your area may have changed!
Start your patients on the road to treating diabetes with Tresiba®
Discover what makes the Tresiba® molecule different
Tresiba® is a long-acting insulin with proven efficacy and a demonstrated safety profile.
Coverage may have changed in your area, and more patients may be covered than you think.
Start your patients on the road to treating diabetes with Tresiba®
Discover what makes the Tresiba® molecule different
Tresiba® is a long-acting insulin with proven efficacy and a demonstrated safety profile.
Coverage may have changed in your area, and more patients may be covered than you think.


The Tresiba® molecule is different by design
The molecular design of Tresiba® provides a steady rate of absorption into the bloodstream, giving it a flat and stable profile.1-3 This slow and steady release allows for around-the-clock glycemic control.

The recommended time between dose increases is 3 to 4 days (the same amount of time it takes to reach steady state).1
Adult patients who miss a dose of Tresiba® should inject their daily dose during waking hours upon discovering the missed dose, then continue with their regular dosing schedule. Ensure that at least 8 hours have elapsed between Tresiba® injections.1

It’s time to have the conversation about insulin and the risks of hypoglycemia
Patients starting on basal insulin may experience hypoglycemia without even understanding what is happening. View some of the risk factors of hypoglycemia, and share this information with your patients as you discuss the signs and symptoms.
For your insulin-naïve patients, consider the results of the DEVOTE study, a landmark safety outcomes trial for adults with type 2 diabetes (T2D) and ASCVD.
Patients starting on basal insulin may experience hypoglycemia without even understanding what is happening. View some of the risk factors of hypoglycemia, and share this information with your patients as you discuss the signs and symptoms.
For your insulin-naïve patients, consider the results of the DEVOTE study, a landmark safety outcomes trial for adults with type 2 diabetes (T2D) and ASCVD.

PRIMARY ENDPOINT
MACE: Noninferiority
Tresiba® U-100 demonstrated no increased risk of major adverse cardiovascular events (MACE) vs insulin glargine U-100 for adults with T2D and ASCVD.4,a
PRIMARY ENDPOINT
MACE: Noninferiority
Tresiba® U-100 demonstrated no increased risk of major adverse cardiovascular events (MACE) vs insulin glargine U-100 for adults with T2D and ASCVD.4,a
SECONDARY ENDPOINT
Significantly lower rates of severe hypoglycemia
The secondary confirmatory endpoint showed Tresiba® U-100 also demonstrated significantly lower rates of severe hypoglycemic events vs insulin glargine U-100.4,b



“The safety outcomes data and other differentiating factors solidified Tresiba® as my go-to basal insulin for patients with type 2 diabetes. I also discuss Tresiba® with my colleagues and encourage them to prescribe Tresiba® for their appropriate patients.”
PHILIP WOODHAM, MD
Endocrinologist
Hackensack, NJ
Help patients navigate savings and coverage options

Study design
DEVOTE4
Population: Adult patients with T2D and ASCVD.
Study design: Treat-to-target, randomized, double-blind, active comparator-controlled, event-driven cardiovascular outcomes trial assessing the noninferiority of once-daily Tresiba® U-100 (n=3818) and once-daily insulin glargine U-100 (n=3819) in terms of the incidence of cardiovascular events.
Primary composite endpoint: Time from randomization to first occurrence of an adjudicated major cardiovascular event (MACE): cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke.
Secondary confirmatory endpoints: The number and incidence of adjudicated events of severeb hypoglycemia, as defined in 2013 by the American Diabetes Association.
aMACE=cardiovascular death, nonfatal MI, or nonfatal stroke.
bSevere hypoglycemia was defined as an episode requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions and during which plasma glucose concentration may not have been available, but where neurological recovery following the return of plasma glucose to normal was considered sufficient evidence that the event was induced by a low plasma glucose concentration.
ASCVD=atherosclerotic cardiovascular disease.